<DOC>
	<DOC>NCT03017313</DOC>
	<brief_summary>The purpose of the protocol, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed</brief_summary>
	<brief_title>To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>Adult men diagnosed of locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy with a 3 or 6 month LHRH analogue including those requiring neoadjuvant or adjuvant androgen deprivation therapy in association with radiotherapy Patients having provided written informed consent Patients mentally fit for completing a selfadministrated questionnaire Patients participating in another clinical study at the time of inclusion Patients with another severe malignant disease Life expectancy of less than 12 months Patients already treated with a LHRH analogue within the last year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>